MICAFUNGIN SODIUM

Post-LOE

micafungin

Biocon

ANDAINTRAVENOUSINJECTABLE

Approved

Oct 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

MICAFUNGIN SODIUM (micafungin) by Biocon is [see microbiology ()]. Approved for acute disseminated candidiasis, abscesses in adult, older. First approved in 2022.

Drug data last refreshed 18h ago

Mechanism of Action

[see Microbiology ()].

Indications (3)

Acute Disseminated Candidiasis Abscesses in adult older

Worked on MICAFUNGIN SODIUM at Biocon? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (20)

NCT03102658Phase 4Completed

Micafungin Pharmacokinetics in Obese Patients

Started Jan 2017

24 enrolled

Morbid Obesity

NCT02440178Phase 2Completed

Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia

Started Sep 2015

66 enrolled

Acute Leukemia

NCT03421002Phase 2Completed

Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis

Started May 2015

35 enrolled

Candidiasis, SystemicCandida Meningitis

NCT02678598N/ACompleted

A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections

Started Mar 2015

2,555 enrolled

Invasive Fungal Infections

NCT02127788N/ACompleted

Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology

Started Jul 2014

150 enrolled

Antifungal ProphylaxisHaemopathy